hotjili.cc-jili fortune
Qualcomm Wins In The Arm LitigationPro Football Hall of Famer Randy Moss reveals cancer diagnosis, 6-hour surgery Pro Football Hall of Fame wide receiver Randy Moss says he is being treated for cancer and is recovering from major surgery. In an appearance on Instagram Live on Friday, Moss introduced himself as a cancer survivor and thanked his “prayer warriors” for their support. Moss says a cancerous mass was found in his bile duct, between his pancreas and liver. He says he had surgery to put a stent in his liver on Thanksgiving and then underwent a 6-hour procedure about a week ago to remove the cancer. He says he was hospitalized for six days and released on Friday. De'Vondre Campbell won't be part of the 49ers after his refusal to enter a game, Kyle Shanahan says SANTA CLARA, Calif. (AP) — San Francisco coach Kyle Shanahan said linebacker De’Vondre Campbell won’t be part of the 49ers moving forward after he refused to enter a game after losing his starting job. Shanahan said the team is still working through the options of how to deal with Campbell after he walked to the locker room in the middle of a 12-6 loss to the Los Angeles Rams. Shanahan says the team is weighing its options, which could include a suspension or release, but that Campbell won't be part of the team for the final three weeks of the season. Trae Young, Hawks hoping to win big in Vegas at the NBA Cup semifinals LAS VEGAS (AP) — Trae Young might be the NBA’s biggest enigma. Young’s fans can point to numbers and say he’s an elite player. His detractors can point to numbers and say he’s overrated. Both arguments have validity. To some, his cocky ways are endearing. To others, they’re infuriating. This can’t be argued: He’s helping Atlanta author one of the season’s surprise stories. The Hawks are in the NBA Cup semifinals, set to play Milwaukee on Saturday before the other semifinal between Oklahoma City and Houston. The title game is Tuesday night. Analysis: Only LeBron James knows what's happening right now, and what's in his future LAS VEGAS (AP) — LeBron James was starring in Las Vegas at this time last year, the headline attraction while he and the Los Angeles Lakers were about to win the inaugural version of the event now known as the NBA Cup. That's not the case this year. “Personal reasons ... he’s taking some time” is what Lakers coach JJ Redick said this week when detailing why James was missing from practice. “Left foot soreness” is the reason why the Lakers have ruled him out of Friday’s game in Minnesota. There’s been trade speculation in recent days. It's all very different than a year ago at Cup time. Yankees get closer Devin Williams from Brewers for Nestor Cortes, Caleb Durbin NEW YORK (AP) — The New York Yankees have acquired All-Star closer Devin Williams from the Milwaukee Brewers for left-hander Nestor Cortes and infield prospect Caleb Durbin. The Yankees also will send $2 million to the Brewers as part of the trade. A 30-year-old right-hander, Williams and his signature “Airbender” changeup are eligible for free agency after the 2025 season. He was diagnosed during spring training with two stress fractures in his back and didn’t make his season debut until July 28. Williams was 14 for 15 in save chances with a 1.25 ERA, striking out 38 and walking 11 in 21 2/3 innings. Cubs acquire All-Star outfielder Kyle Tucker in trade with the Astros CHICAGO (AP) — The Chicago Cubs have acquired All-Star outfielder Kyle Tucker in a trade with the Houston Astros, paying a big price for one of baseball’s best hitters. The Cubs sent third baseman Isaac Paredes, right-hander Hayden Wesneski and Cam Smith, one of their top infield prospects, to the Astros for Tucker, who is eligible for free agency after the 2025 season. Tucker was limited to 78 games this year because of a fractured right shin, but he hit .289 with 23 homers and 49 RBIs for the AL West champions. New West Virginia coach Rich Rodriguez says leaving for Michigan 17 years ago was a 'mistake' MORGANTOWN, W.Va. (AP) — Rich Rodriguez says he regrets leaving West Virginia 17 years ago. Rodriguez was introduced as the coach at his alma mater on Friday. Based on the welcome he got from the thousands of West Virginia fans in attendance, much seems to be forgiven. Rodriguez told the crowd that he never should have left his home state. The 61-year-old coach says he's grown both as a person and a coach throughout his long career, and that his departure at the end of the 2007 season for a head coaching job at Michigan was a mistake. Rodriguez went 60-26 at West Virginia from 2001 to 2007. Lindsey Vonn to enter World Cup ski races next weekend in Switzerland in her comeback at age 40 BEAVER CREEK, Colo. (AP) — Lindsey Vonn will return to World Cup ski racing next weekend for a pair of super-G events in St. Moritz, Switzerland, as she continues her comeback at 40 years old. Vonn teased her return in an Instagram post through her sponsor, Red Bull, on Friday morning. She said “I hear St. Moritz is pretty nice this time of year.” The U.S. Ski Team then confirmed she will race in St. Moritz. She’s won five of her 82 World Cup races on the venue at St. Moritz. Picabo Street, a two-time Olympic medalist and Vonn’s former teammate, says “it’s the coolest thing ever.” Woman who falsely accused Duke lacrosse players of rape in 2006 publicly admits she lied RALEIGH, N.C. (AP) — The woman who in 2006 falsely accused three Duke University lacrosse players of raping her has admitted publicly for the first time that she made up the story. The accusations made national headlines at the time, stirring tensions about race, class and the privilege of college athletes. Crystal Mangum, who is Black, said in an interview with the “Let’s Talk with Kat” podcast that she “made up a story that wasn’t true” about the white players who attended a party where she was hired to perform as a stripper “because I wanted validation from people and not from God.” The former Duke players were declared innocent in 2007 after Mangum’s story fell apart under legal scrutiny. Belichick's bid to reshape football at UNC another sign of rising pro influence on college level CHAPEL HILL, N.C. (AP) — North Carolina's hiring of NFL coaching great Bill Belichick marks another sign of the growing influence of the NFL on college football. The challenges of managing the transfer portal and looming revenue sharing for athletes has led teams to take on more NFL-like structures to their programs. Belichick is set to structure North Carolina's program like an NFL front office. That includes hiring former NFL executive Michael Lombardi as general manager. At Florida, coach Billy Napier is interviewing general managers while saying the program is going to “a business model” to deal with a “major math puzzle.”
Summary: LOS ANGELES , Dec. 9, 2024 /PRNewswire/ -- VCA Animal Hospitals , a leader in comprehensive veterinary services and Antech , a leader in veterinary diagnostics, today published its Six-Step Framework for Companion Animal Public Health Collaboration, detailing how One Health organizations can integrate pets into a nationwide health response. This innovative framework outlines the necessary considerations and steps to quickly activate this response lever as part of public safety efforts. It emphasizes the importance of collaboration between veterinary professionals, public health officials, and diagnostic experts to create a seamless and effective response system. Prior to the outset of the COVID-19 pandemic, approaches to understand the impacts of infectious disease outbreaks such as SARS-CoV-2, the virus responsible for COVID-19, on pets were limited and fragmented. A recent VCA study published in Viruses highlights the effectiveness of this new six-step framework in action with VCA and Antech working together to implement rapid-response monitoring and disease detection protocols. This collaboration enabled swift identification and management of COVID-19 cases, demonstrating the potential of the framework to address a critical knowledge gap bridging human and pet health during an emerging public health pandemic. "Traditionally, pets have largely been ignored in public health surveillance, but we want to change that," said Anne Kimmerlein DVM, MPVM, DACVPM, Veterinary Epidemiologist for VCA Animal Hospitals. "Thanks to the participation of our Associates and their pets, we were able to show the impact that the private veterinary sector can have when we come together to address an emerging public health threat. Based on that initial work, we've created a framework for continued and expanded One Health collaboration." The study involved a nationwide approach, focusing on households with confirmed SARS-CoV-2 infections in humans. Pets in these households were monitored for clinical signs consistent with SARS-CoV-2, and samples were collected for PCR and serological testing. The study included 747 dogs and 253 cats. The study highlighted the significance of being watchful of close human-animal contact and preventive measures to reduce transmission risks. The results indicated that pets can contract SARS-CoV-2, primarily through close contact with infected humans. While most pets showed mild or no symptoms, the study nonetheless underscored the recommendation for preventive measures such as good hand hygiene around pets to minimize transmission risks. The findings also demonstrated the potential for pets to seroconvert and develop antibodies, indicating exposure to the virus. "The results of this study show a significant step in advancing our understanding of how closely human and animal health are intertwined – and it was only possible through close collaboration between VCA and our team at Antech," said Christian Leutenegger , Dr. Med. Vet., Ph.D., FHV, Vice President of R&D, Assay Development at Antech Diagnostics . "The research provides a blueprint for continued ongoing collaboration to examine other types of infectious diseases that could impact our pets." VCA and Antech's six-step framework for One Health collaboration sets a new standard for integrating pets into nationwide health responses. By fostering collaboration and leveraging advanced diagnostic tools, this approach helps deliver a swift and effective response to public health crises. The success of the COVID-19 study serves as a testament to the potential of this innovative strategy. "Our commitment to One Health principles has never been stronger," said Marie Kerl , DVM, MPH, MBA, DACVIM, DACVECC and Chief Medical Officer for VCA Animal Hospitals. "By integrating pets into our nationwide health response, we can ensure a more comprehensive approach to public safety and health." To learn more about this groundbreaking framework, visit " Six-Step Framework for Companion Animal Public Health Collaboration ." About VCA Animal Hospitals A leader in veterinary care, VCA Animal Hospitals is committed to caring for the future of veterinary medicine. We are a family of hometown animal hospitals determined to positively impact pets, people, and our communities. From general practice to emergency and specialty care, VCA delivers world-class medicine to more than four million pets each year. Our national network of hospitals invests in cutting-edge tools, training and technology that enables our Associates to lead the industry today and into tomorrow. Among our talented 35,000 Associates are nearly 7,000 veterinarians – including 430 who are board-certified specialists – nearly 4,000 credentialed veterinary technicians and more than 10,000 veterinary assistants – all dedicated to giving pets the very best in medical care. As part of the Mars Petcare family of businesses, VCA is committed to its Purpose: A BETTER WORLD FOR PETS. To learn more about VCA, visit vca.com . About Mars Veterinary Health Mars Veterinary Health is a global division of Mars Petcare dedicated to delivering high-quality pet healthcare to further its collective Purpose: A BETTER WORLD FOR PETS. Mars Veterinary Health's 70,000 Associates across 3,000 global veterinary clinics put pets, people, and the planet first. The Mars Veterinary Health family includes Associates at AniCura, Banfield, BluePearl, Creature Comforts, Gentle Oak, Hillside, Linnaeus, Mount Pleasant, Tai Wai , VCA, VES, and VSH who demonstrate compassion and expertise while enabling 35 million pet visits each year. Learn more at marsveterinaryhealth.com . About Antech Antech is a leader in veterinary diagnostics, driven by our passion for innovation that delivers better animal health outcomes. Our products and services span 90+ reference laboratories around the globe; in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; veterinary imaging and technology; veterinary professional education and training; and board-certified specialist support services. As part of the Mars Petcare family of businesses, Antech is committed to its Purpose: A BETTER WORLD FOR PETS. Learn more at AntechDiagnostics.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/vca-animal-hospitals-and-antech-advocate-for-more-comprehensive-pet-data-in-public-health-reporting-recommend-six-step-framework-for-one-health-collaboration-302326701.html SOURCE VCA Animal Hospitals
A widely expected increase in the October Personal Consumption Expenditures (PCE) price index — commonly regarded as the Federal Reserve's preferred inflation gauge — triggered fresh losses for the U.S. dollar, while Treasury yields and U.S. stocks also slid in tandem. By 11:10 a.m. ET in New York, the U.S. Dollar Index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF UUP , was down 0.8%, reflecting broad weakness in the greenback. Meanwhile, 10-year Treasury yields fell by five basis points to 4.26%, and the S&P 500, replicated by the SPDR S&P 500 ETF Trust SPY , dropped 0.4%. Tech stocks were hit harder, with the Nasdaq 100 — tracked by the Invesco QQQ Trust, Series 1 QQQ — plunging 1.3%. The headline PCE price index rose by 2.3% year-over-year in October, up from 2.1% in September, in line with forecasts. Core PCE inflation, which strips out volatile energy and food prices, also ticked higher, climbing from 2.7% to 2.8% annually, meeting economist predictions. In a positive twist, personal spending and income data slightly beat expectations. Meanwhile, the second estimate for third-quarter U.S. GDP growth remained unchanged at a solid 2.8% annualized rate. Joseph Brusuelas , economist at RSM US, highlighted the strength of household finances ahead of the critical holiday shopping season. “Strong personal spending and a 0.6% increase in personal income underscores just how robust the economy and households remain as we approach Black Friday and year-end 2024,” Brusuelas said. Despite inflationary signals, Brusuelas maintains that the Federal Reserve is likely to lower interest rates by 25 basis points during its Dec. 18 meeting. Market-implied probabilities echoed this sentiment, with a 70% chance of a rate cut priced into futures markets. Yet, while U.S. economic data took center stage, Wednesday's market action appeared more influenced by carry-trade unwinding and growing speculation around a potential Bank of Japan (BOJ) interest rate hike in December. The Japanese yen jumped 1.2% against the dollar, extending its winning streak to three consecutive sessions. Such a strong daily move by the yen certainly strides with statistics revealing an October U.S. inflation uptick. “Investors are betting on an interest-rate hike from the Bank of Japan next month,” noted BBVA forex strategist Alejandro Cuadrado in a client note on Tuesday. The interest rate futures curve now implies a 65% probability of a BOJ rate hike in December, compared to just 30% at the start of November . The yen's Wednesday outperformance has revived memories of the carry-trade turmoil from early August, when a sudden shift in yen-dollar dynamics sent shockwaves across global markets. Since that episode, the yen had depreciated by over 5% against the dollar, weighed down further by the victory of Donald Trump in the 2024 U.S. presidential elections. Read Now: Amazon Dominates Holiday Shopping As Black Friday Spending Soars: Goldman Sachs Photo: Pixabay © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Russian central bank holds rates steady even as war against Ukraine fuels inflationCalandra Turkey Challenge donates 800 birds to Rome Rescue Mission
Hungary’s Orbán meets with Trump and Musk
Japanese researchers test pioneering drug to regrow teeth
The Saints are making contingency plans to play without QB Derek Carr as they try to stay aliveThe Analyst Verdict: Rigetti Computing In The Eyes Of 5 ExpertsGREENVILLE, N.C. (AP) — Darryl Simmons II's 29 points helped Gardner-Webb defeat East Carolina 84-79 on Saturday night. Simmons also had five rebounds for the Runnin' Bulldogs (5-8). Anthony Selden shot 5 for 13 (3 for 6 from 3-point range) and 5 of 8 from the free-throw line to add 18 points. Isaiah Richards went 6 of 8 from the field to finish with 12 points. The victory snapped a five-game slide for the Runnin' Bulldogs. The Pirates (8-5) were led in scoring by RJ Felton, who finished with 19 points. Joran Riley added 18 points, eight rebounds, four steals and two blocks for East Carolina. Cam Hayes also recorded 18 points and four assists. Simmons scored 11 points in the first half and Gardner-Webb went into the break trailing 37-35. Simmons' 18-point second half helped Gardner-Webb finish off the five-point victory. ___ The Associated Press created this story using technology provided by and data from . The Associated PressCity U21s chief 'really disappointed' by Boro defeat
Markey said that he will vote “no" to Kennedy’s appointment, and that he thinks after the Senate goes through its “advise and consent" role in the process and holds hearings on the matter, many of his Republican colleagues will as well.
SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: Phase 3 CAHtalyst Adult Study: CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.
PM launches project to restore Kachhi canalNone